Helex Bio
Company Type: Therapeutic development
Main focus: Developing gene-editing based therapeutics to treat genetic kidney diseases
Company stage: Pre-clinical
Diseases: Autosomal dominant polycystic kidney disease, inherited retinal dystrophies, and other genetic disorders
Genome-editing tool: CRISPR-Cas9
Funding stage: Private
Location: New York, New York, USA
Website: www.helex.bio
Pipeline: www.helex.bio/technology
Partners:
Helex Bio is a pre-clinical biotechnology company focused on advancing safer in vivo gene-editing therapies to treat genetic kidney diseases and other genetic disorders. The company has developed a proprietary lipid nanoparticle delivery system for safe and effective delivery to the kidneys, as well as EPIC-Cure™, a proprietary drug design platform. EPIC-Cure™ seeks to provide a genome-encompassing, data-driven gene-editing drug design for higher precision of editing.